Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | FNTA | P49354 | 3/20 | 0.46 |
| ▸ | FNTB | P49356 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL4494758 | 0.96 | HTT (0.47) | HTTFNTAFNTBALDH1A1KMT2A | |
| SCHEMBL1573289 | 0.89 | HTT (0.47) | HTTFNTAFNTBALDH1A1KMT2A | |
| SCHEMBL320949 | 0.88 | HTT (0.46) | HTTFNTAFNTBALDH1A1KMT2A | |
| SCHEMBL4501200 | 0.87 | MAPT (0.45) | HTTALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL145931 | 0.86 | HTT (0.45) | HTTFNTAFNTBALDH1A1KMT2A | |
| SCHEMBL3954660 | 0.85 | HTT (0.44) | HTTFNTAFNTBALDH1A1KMT2A | |
| Water SCHEMBL4620128 | 0.85 | HTT (0.43) | HTTFNTAFNTBALDH1A1KMT2A | |
| SCHEMBL1572767 | 0.84 | HTT (0.54) | HTTFNTAFNTBALDH1A1KMT2A | |
| SCHEMBL13918682 | 0.84 | ALDH1A1 (0.45) | HTTFNTAFNTBALDH1A1KMT2A | |
| SCHEMBL1572805 | 0.82 | MAPT (0.47) | HTTALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| CN-101384258-B | FGF Receptor Agonist Dimeric Compounds | SANOFI AVENTIS | 2013-06-26 | — | — | CN | disclosed |
| EP-2018165-B1 | FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI AVENTIS (FR) | 2011-04-13 | — | — | EP | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
| CN-101384258-A | FGF receptor agonist dimeric compounds | SANOFI AVENTIS (FR) | 2009-03-11 | — | — | CN | disclosed |
| EP-2018165-A1 | FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS | Sanofi-Aventis (FR) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007080325-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007080325-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | HTT 4673/4885FNTA 3865/4885FNTB 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.